Deutsche Bank AG bought a new position in shares of CVS Health Corporation (NYSE:CVS - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 4,510,716 shares of the pharmacy operator's stock, valued at approximately $466,634,000. Deutsche Bank AG owned approximately 0.35% of CVS Health as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of CVS. Handelsbanken Fonder AB lifted its position in shares of CVS Health by 83.6% in the second quarter. Handelsbanken Fonder AB now owns 1,089,694 shares of the pharmacy operator's stock valued at $112,729,000 after acquiring an additional 496,124 shares in the last quarter. State Street Corp increased its position in shares of CVS Health by 2.1% during the fourth quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator's stock worth $4,776,182,000 after purchasing an additional 1,245,457 shares in the last quarter. Legal & General Group Plc raised its stake in CVS Health by 0.3% in the 4th quarter. Legal & General Group Plc now owns 9,309,182 shares of the pharmacy operator's stock valued at $738,777,000 after purchasing an additional 31,249 shares during the last quarter. Hussman Strategic Advisors Inc. acquired a new position in CVS Health in the 4th quarter valued at $3,333,000. Finally, SG Americas Securities LLC grew its holdings in shares of CVS Health by 13.7% during the first quarter. SG Americas Securities LLC now owns 1,228,069 shares of the pharmacy operator's stock worth $87,459,000 after buying an additional 147,827 shares in the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In related news, Director Larry Robbins sold 1,018,000 shares of the company's stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $93.82, for a total value of $95,508,760.00. Following the transaction, the director directly owned 5,195,261 shares in the company, valued at approximately $487,419,387.02. This represents a 16.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.85% of the company's stock.
CVS Health Trading Down 3.3%
Shares of CVS opened at $93.99 on Tuesday. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.74. CVS Health Corporation has a 12-month low of $69.40 and a 12-month high of $110.68. The firm has a 50-day moving average price of $102.46 and a 200 day moving average price of $88.41. The firm has a market capitalization of $120.21 billion, a P/E ratio of 24.87, a P/E/G ratio of 0.93 and a beta of 0.61.
CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.71. The firm had revenue of $106.10 billion during the quarter, compared to analysts' expectations of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. CVS Health's revenue was up 7.3% compared to the same quarter last year. During the same period last year, the business earned $1.81 earnings per share. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Sell-side analysts forecast that CVS Health Corporation will post 8.02 EPS for the current year.
CVS Health Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd were given a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend was Thursday, July 23rd. CVS Health's payout ratio is presently 70.37%.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on the stock. Piper Sandler reissued an "overweight" rating and issued a $113.00 price target on shares of CVS Health in a research note on Monday, June 1st. Truist Financial upped their price objective on shares of CVS Health from $108.00 to $118.00 and gave the company a "buy" rating in a research note on Tuesday, July 14th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of CVS Health from $88.00 to $92.00 and gave the company a "buy" rating in a report on Thursday, May 7th. Wall Street Zen upgraded CVS Health from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 8th. Finally, HSBC restated a "hold" rating and issued a $103.00 price target on shares of CVS Health in a research report on Monday, July 6th. Twenty-two analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, CVS Health presently has a consensus rating of "Moderate Buy" and an average price target of $106.75.
View Our Latest Stock Analysis on CVS
CVS Health Company Profile
(
Free Report)
CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.
Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.
See Also
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.
Get This Free Report
